Kindred Biosciences – Consensus Indicates Potential 2.8% Upside

Broker Ratings

Kindred Biosciences found using ticker (KIN) now have 6 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The range between the high target price and low target price is between 11 and 9 with the average target price sitting at 9.5. With the stocks previous close at 9.24 this indicates there is a potential upside of 2.8%. The 50 day MA is 9.2 and the 200 moving average now moves to 6.64. The market capitalisation for the company is $421m. You can visit the company’s website by visiting:

Kindred Biosciences, a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California. As of August 27, 2021, Kindred Biosciences operates as a subsidiary of Elanco Animal Health Incorporated.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index